Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effectiveness of Online Gut-Directed Hypnotherapy and Movement Motivational and Self-management Training for Abdominal Pain Disorders in Adolescents (HIPMO)

12 november 2026 bijgewerkt door: János Major, Bethesda Children's Hospital

Effectiveness of Online Hypnotherapy and Movement Motivation Training for Abdominal Pain Disorders in Adolescents

The present study is an online-based investigation involving adolescents with abdominal pain disorders, defined as recurrent abdominal pain persisting for at least two months. The study aims to evaluate the feasibility, acceptability, and effectiveness of online therapeutic interventions in comparison with usual pediatric gastroenterological care.

The study has two primary objectives. The first is to make two therapeutic interventions-Movement Motivation and Self-management Training (M3 Training) and gut-directed hypnotherapy-available online in Hungarian to young people with abdominal pain disorders and their families. Providing these interventions in an online format may facilitate easier and more timely access to therapeutic support for adolescents experiencing abdominal symptoms.

The second objective is to evaluate the effectiveness of the two online interventions. Specifically, the effectiveness of M3 Training and gut-directed hypnotherapy will be assessed both as individual interventions and in combination, and compared with usual pediatric gastroenterological care. This evaluation will assess whether the online interventions, delivered individually or in combination, offer effective therapeutic options for adolescents with abdominal pain disorders, focusing on both primary and secondary outcomes.

Studie Overzicht

Toestand

Nog niet aan het werven

Studietype

Ingrijpend

Inschrijving (Geschat)

800

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • Budapest
      • Budapest, Budapest, Hongarije, 1146
        • HRC Bethesda Children's Hospital
        • Onderonderzoeker:
          • Katalin Forgács-Kristóf, MSc
        • Contact:
        • Onderonderzoeker:
          • Adrienn Vargay, PhD
        • Onderonderzoeker:
          • Sára Bencsik, MD
        • Onderonderzoeker:
          • Nándor Hajdú, PhD
        • Onderonderzoeker:
          • Katalin Eszter Müller, MD, PhD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

12 jaar tot 18 jaar (Kind, Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

Following the minimum diagnostic work-up performed by a gastroenterologist, including:

  • celiac disease serology;
  • C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR);
  • complete blood count (CBC);
  • total protein;
  • albumin;
  • aspartate aminotransferase (AST; GOT);
  • alanine aminotransferase (ALT; GPT);
  • gamma-glutamyl transferase (GGT);
  • lactate dehydrogenase (LDH);
  • alkaline phosphatase (ALP);
  • urea;
  • creatinine;
  • iron studies;
  • urinalysis, at minimum using a urine dipstick;
  • fecal calprotectin or fecal occult blood testing.

Participants will be included in the study based on symptoms consistent with abdominal pain disorders according to the Rome V criteria and the following inclusion criteria:

  • Continuous or regularly recurrent abdominal pain persisting for at least 3 months.
  • No identifiable underlying organic disease that could explain the abdominal pain.
  • Able to care for themselves, capable of self-care and able to understand and follow the study procedures.
  • Able to read and write in Hungarian.
  • Has access to the internet.

Exclusion Criteria:

  • Known severe psychiatric disorder
  • Epilepsy
  • Gastrointestinal disease requiring treatment and associated with pain symptoms
  • Proctalgia fugax
  • Intellectual disability.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Geen tussenkomst: Standard care

In the standard care control group, as in the intervention groups, participants will use an online platform (hasifajdalomkezeles.hu) to record their adherence to the treatment recommended by their gastroenterologist. The website does not include any therapeutic videos or active intervention. Its sole function is to support repeated online questionnaire-based data collection assessing treatment fidelity, adherence, and perceived effectiveness of the treatment.

The primary and secondary outcome questionnaires become available at predefined time points over a 12-week period.

Experimenteel: Gut-Focused Hypnosis Program

The hypnosis arm is delivered through the same main study website (hasifajdalomkezeles.hu), presenting content developed based on the Dutch model of gut-directed hypnosis (www.hypnosis4abdominalpain.com), adapted with permission to Hungarian. The program is primarily based on video and audio materials and follows a predefined, standardised structure.

The 12-week-long intervention content has a linear format consisting of sequential modules that introduce: the concept of abdominal pain disorders; the development of bowel hypersensitivity; the principles of medical hypnosis; and the role of hypnosis in the treatment of abdominal pain.

This section is accompanied by weekly audio-based exercises that are designed to align with the original Dutch model. Adolescents are encouraged to complete the exercises that correspond to the weekly audio sessions, promoting deeper engagement and understanding of the material.

The hypnosis website is non-adaptive and non-personalised.

The hypnosis arm is delivered through the same main study website (hasifajdalomkezeles.hu), presenting content developed based on the Dutch model of gut-directed hypnosis ( www.hypnosis4abdominalpain.com), adapted with permission to Hungarian. The program is primarily based on video and audio materials and follows a predefined, standardised structure.

The 12-week-long intervention content has a linear format consisting of sequential modules that introduce: the concept of abdominal pain disorders; the development of bowel hypersensitivity; the principles of medical hypnosis; and the role of hypnosis in the treatment of abdominal pain.

This section is accompanied by weekly audio-based exercises that are designed to align with the original Dutch model. Adolescents are encouraged to complete the exercises that correspond to the weekly audio sessions, promoting deeper engagement and understanding of the material.

The hypnosis website is non-adaptive and non-personalised.

Experimenteel: M3 Training

M3 Training is a fully digitalised, 12-week online movement-motivation program delivered through the same website (hasifajdalomkezeles.hu). The previously developed and tested M3 Training program is fully adapted for digital delivery, with content specifically designed to support young people with chronic abdominal pain in developing their own movement program.

During the first two weeks, the video series guides participants through the process of designing an individually developed movement program, which they then carry out over 3 months. From weeks 3 to 12, participants receive ongoing motivational videos and supporting materials aimed at maintaining engagement and supporting implementation of their movement plan. Throughout this period, participants are able to modify and further develop their movement program.

Participants provide written responses to questions linked to the videos through the website, allowing them to reflect on their experiences and development throughout.

M3 Training is a fully digitalised, 12-week online movement-motivation program delivered through the same website (fasifajdalomkezeles.hu). The previously developed and tested M3 Training program is fully adapted for digital delivery, with content specifically designed to support young people with chronic abdominal pain in developing their own movement program.

During the first two weeks, the video series guides participants through the process of designing an individually developed movement program, which they then carry out over 3 months. From weeks 3 to 12, participants receive ongoing motivational videos and supporting materials aimed at maintaining engagement and supporting implementation of their movement plan. Throughout this period, participants are able to modify and further develop their movement program.

Participants provide written responses to questions linked to the videos through the website, allowing them to reflect on their experiences and development throughout.

Experimenteel: Combined Hypnosis + M3 Training

This arm represents an integrated version of the hypnosis program and M3 Training, combining the two existing interventions into a single 12-week online program. Users access both therapeutic components through the same website (hasifajdalomkezeles.hu). During the 12-week-long joint program the hypnosis-related content and the M3 Training videos are released according to a coordinated schedule. The aim is not simply to provide the two interventions in parallel, but to achieve structured integration, ensuring that the two approaches complement one another.

The hypnosis arm is delivered through the same main study website (hasifajdalomkezeles.hu), presenting content developed based on the Dutch model of gut-directed hypnosis ( www.hypnosis4abdominalpain.com), adapted with permission to Hungarian. The program is primarily based on video and audio materials and follows a predefined, standardised structure.

The 12-week-long intervention content has a linear format consisting of sequential modules that introduce: the concept of abdominal pain disorders; the development of bowel hypersensitivity; the principles of medical hypnosis; and the role of hypnosis in the treatment of abdominal pain.

This section is accompanied by weekly audio-based exercises that are designed to align with the original Dutch model. Adolescents are encouraged to complete the exercises that correspond to the weekly audio sessions, promoting deeper engagement and understanding of the material.

The hypnosis website is non-adaptive and non-personalised.

M3 Training is a fully digitalised, 12-week online movement-motivation program delivered through the same website (fasifajdalomkezeles.hu). The previously developed and tested M3 Training program is fully adapted for digital delivery, with content specifically designed to support young people with chronic abdominal pain in developing their own movement program.

During the first two weeks, the video series guides participants through the process of designing an individually developed movement program, which they then carry out over 3 months. From weeks 3 to 12, participants receive ongoing motivational videos and supporting materials aimed at maintaining engagement and supporting implementation of their movement plan. Throughout this period, participants are able to modify and further develop their movement program.

Participants provide written responses to questions linked to the videos through the website, allowing them to reflect on their experiences and development throughout.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pain intensity (proportion of patients with ≥30% improvement in abdominal pain) measured by Numerical Rating Scale
Tijdsspanne: From enrollment to the end of treatment at 12 weeks.

≥30% reduction in pain intensity is our main outcome. Pain intensity will be assessed using an 11-point Numerical Rating Scale (NRS; 0-10), which is a validated measure of self-reported pain intensity in children and adolescents (Miró et al., 2009).

From enrollment to the end of treatment at 12 weeks.
Quality of Life measured by The Pediatric Quality of Life Inventory
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

The Pediatric Quality of Life Inventory (PedsQL) is a validated questionnaire designed to assess health-related quality of life in children and adolescents.

From enrollment to the end of treatment at 12 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Functional Disability assessed by Functional Disability Inventory
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

The Functional Disability Inventory (FDI) is a 15-item self-report measure assessing limitations in everyday physical, social, and school-related activities. It has been extensively validated in children and adolescents, including a large sample of 596 patients aged 8-17 years with chronic abdominal pain (Walker & Greene, 1991; Claar & Walker, 2006). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Anxiety and Depression measured by Revised Children's Anxiety and Depression Scale (RCADS)
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

The Revised Children's Anxiety and Depression Scale (RCADS) is a 47-item self-report questionnaire assessing symptoms of anxiety and depression in children and adolescents and has demonstrated good psychometric properties in both community and clinical populations (Chorpita et al., 2000; Chorpita et al., 2005). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Gastrointestinal symptom-specific anxiety measured by Visceral Sensitivity Index
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

The original Visceral Sensitivity Index (VSI) is a 15-item, unidimensional self-report questionnaire developed to assess gastrointestinal symptom-specific anxiety-that is, anxiety, worry, and fear related to gastrointestinal sensations, symptoms, and the situations in which these symptoms may occur. It was developed and validated in 96 adult patients with irritable bowel syndrome (IBS) and showed excellent reliability together with good content, convergent, divergent, and predictive validity (Labus et al., 2004). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Different cognitive, behavioural, and interpersonal strategies used by children to cope with pain assessed by Pain Coping Questionnaire
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

The Pain Coping Questionnaire (PCQ) is a 39-item self-report measure assessing different cognitive, behavioural, and interpersonal strategies used by children to cope with pain. It was developed for children and adolescents and has been validated from approximately 8 years of age, including populations with recurrent pain (Reid et al., 1998). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Missing school days collected from parents
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

School absence will be assessed as the parent-reported number of school days missed because of abdominal pain or gastrointestinal symptoms during a predefined recall period. Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Sleep characteristics assessed using study-specific self-report items
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

Sleep characteristics will be assessed using study-specific self-report items covering perceived sleep quality, average nightly sleep duration, and frequency of daytime naps.

From enrollment to the end of treatment at 12 weeks
Intervention Satisfaction and Patient Global Impression of Change assessed by open-ended question
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

Patient satisfaction will be explored using the following open-ended question: "What story would you tell your best friend about your experience with the therapy over the past 12 weeks?"

Patient Global Impression of Change will be measured through the following question:

Since the start of the study, my overall status is: options range from "Very Much Improved" to "Very Much Worse" Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks
Website engagement collected via webpage
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

Website monitoring will include the number and timing of logins, the duration and frequency of listening to the audio recordings, the duration and frequency of viewing the M3 videos, whether each audio recording was listened to at least once, whether each video was viewed at least once, and whether all questions were answered; if not, the number and identity of unanswered questions will also be recorded.

From enrollment to the end of treatment at 12 weeks
Adequate Relief of Abdominal Pain and/or Discomfort assessed using a single dichotomous (yes/no) question.
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

Proportion of participants reporting adequate relief of abdominal pain and/or discomfort during the preceding week compared with baseline, assessed using a single dichotomous (yes/no) question.

From enrollment to the end of treatment at 12 weeks

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Adverse event assessed by open-ended questions
Tijdsspanne: From enrollment to the end of treatment at 12 weeks

Adverse events will be monitored prospectively throughout the intervention period. An adverse event will be defined as any new or worsening unfavourable physical or psychological health-related occurrence during study participation, irrespective of whether it is considered to be related to the intervention. At each scheduled assessment, participants will be asked about any new or worsening health-related problems since the previous assessment. If an adverse event is reported, a brief description of the event, its impact on daily activities, whether medical attention was required, and whether it resulted in modification or discontinuation of the intervention will be recorded. Reported events will subsequently be reviewed by the study team with respect to severity, seriousness, expectedness, and possible relatedness to the intervention (Junqueira et al., 2023; Burns et al., 2024). Both the child and parent versions of the questionnaire will be administered.

From enrollment to the end of treatment at 12 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 december 2030

Studie voltooiing (Geschat)

1 december 2030

Studieregistratiedata

Eerst ingediend

12 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • BM/9151-1/2024

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren